Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:BFRI NASDAQ:CARM NASDAQ:GLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.57-1.3%$1.71$1.41▼$5.01$9.12M1.2938,126 shs19,931 shsBFRIBiofrontera$0.89+4.1%$0.88$0.54▼$2.22$8.99M0.5267,825 shs78,054 shsCARMCarisma Therapeutics$0.22-5.7%$0.35$0.14▼$1.27$8.98M1.795.70 million shs69.60 million shsGLMDGalmed Pharmaceuticals$1.27-8.0%$1.71$1.15▼$23.80$2.10M0.581.05 million shs180,817 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-0.94%-0.94%-9.69%-10.96%-54.71%BFRIBiofrontera-0.99%-4.65%-18.90%+49.39%-16.52%CARMCarisma Therapeutics+0.88%-0.61%-32.76%+18.20%-80.34%GLMDGalmed Pharmaceuticals-0.72%-6.12%-22.91%-4.17%-57.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics3.1993 of 5 stars3.55.00.00.02.00.81.3BFRIBiofrontera3.0811 of 5 stars3.55.00.00.03.50.00.6CARMCarisma Therapeutics2.8244 of 5 stars3.45.00.00.02.20.80.6GLMDGalmed Pharmaceuticals1.7177 of 5 stars0.05.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50890.42% UpsideBFRIBiofrontera 3.00Buy$2.75210.35% UpsideCARMCarisma Therapeutics 2.71Moderate Buy$1.93795.35% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest GLMD, CARM, BFRI, and APRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025CARMCarisma TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$1.007/15/2025CARMCarisma TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea TherapeuticsN/AN/AN/AN/A$2.30 per shareN/ABFRIBiofrontera$37.32M0.24N/AN/A($0.46) per share-1.93CARMCarisma Therapeutics$10.77M0.83N/AN/A($1.10) per share-0.20GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.32N/AN/AN/A-1,645.01%-78.90%-62.67%11/6/2025 (Estimated)BFRIBiofrontera-$17.76M-$2.26N/AN/AN/A-42.34%-1,104.09%-82.28%11/12/2025 (Estimated)CARMCarisma Therapeutics-$60.48M-$1.56N/AN/AN/A-254.28%N/A-192.17%11/5/2025 (Estimated)GLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-32.21%-28.59%11/12/2025 (Estimated)Latest GLMD, CARM, BFRI, and APRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BFRIBiofrontera-$0.45-$0.57-$0.12-$0.57$8.30 million$9.03 million8/12/2025Q2 2025APREAprea Therapeutics-$0.77-$0.53+$0.24-$0.53N/A$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/ACARMCarisma TherapeuticsN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.345.34BFRIBiofrontera8.990.960.75CARMCarisma TherapeuticsN/A0.480.48GLMDGalmed PharmaceuticalsN/A9.029.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%BFRIBiofrontera10.08%CARMCarisma Therapeutics44.27%GLMDGalmed Pharmaceuticals76.14%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%BFRIBiofrontera4.80%CARMCarisma Therapeutics6.90%GLMDGalmed Pharmaceuticals19.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.83 million5.03 millionNo DataBFRIBiofrontera7010.14 million9.65 millionNo DataCARMCarisma Therapeutics2041.79 million38.91 millionNo DataGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableGLMD, CARM, BFRI, and APRE HeadlinesRecent News About These CompaniesGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 28 at 12:12 PM | finanznachrichten.deGalmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 28 at 8:00 AM | prnewswire.comGalmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder ValueAugust 25, 2025 | prnewswire.comGalmed Pharmaceuticals Amends Articles of Association Following Shareholder ApprovalAugust 15, 2025 | msn.comGalmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of QuorumAugust 14, 2025 | tipranks.comGalmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASHMay 27, 2025 | prnewswire.comGALMED PHARMACEUTICALS Earnings Results: $GLMD Reports Quarterly EarningsMay 24, 2025 | nasdaq.comGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 22, 2025 | finanznachrichten.deGalmed Pharmaceuticals: Q1 Earnings SnapshotMay 22, 2025 | houstonchronicle.comHGalmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 22, 2025 | prnewswire.comGalmed Pharmaceuticals Ltd.: Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC ModelsMay 13, 2025 | finanznachrichten.deGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC ModelsMay 13, 2025 | finance.yahoo.comGalmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’May 7, 2025 | msn.comGalmed Pharmaceuticals Ltd.: Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly EnhancesMay 6, 2025 | finanznachrichten.deGalmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsMay 6, 2025 | prnewswire.comAnalysts Conflicted on These Healthcare Names: Galmed Pharmaceuticals (GLMD) and Regeneron (REGN)April 30, 2025 | theglobeandmail.comGalmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual FormulationApril 28, 2025 | prnewswire.comGalmed launches VCU collaboration to tackle drug resistance in GI cancersApril 19, 2025 | markets.businessinsider.comGalmed partners with VCU to target drug resistanceApril 17, 2025 | thepharmaletter.comTGalmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI CancersApril 17, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLMD, CARM, BFRI, and APRE Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.56 -0.02 (-1.26%) Closing price 03:59 PM EasternExtended Trading$1.60 +0.04 (+2.30%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Biofrontera NASDAQ:BFRI$0.89 +0.03 (+4.06%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.01 (-0.58%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Carisma Therapeutics NASDAQ:CARM$0.22 -0.01 (-5.70%) Closing price 04:00 PM EasternExtended Trading$0.47 +0.26 (+119.53%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Galmed Pharmaceuticals NASDAQ:GLMD$1.27 -0.11 (-7.97%) Closing price 03:59 PM EasternExtended Trading$1.32 +0.04 (+3.54%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access